Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      

This page is updated frequently with new Cholesterol-related patent applications.




Date/App# patent app List of recent Cholesterol-related patents
07/14/16
20160199497 
 Cholesterol ester-depleting nanomedicine for non-toxic cancer chemotherapy patent thumbnailCholesterol ester-depleting nanomedicine for non-toxic cancer chemotherapy
The present invention provides a formulation for reducing the hydrophobicity of acat-1 inhibitors. Methods for using the formulation of the present invention are also provided..
Purdue Research Foundation


07/14/16
20160199451 
 Composition for treating hyperlipidemia comprising oxyntomodulin derivative patent thumbnailComposition for treating hyperlipidemia comprising oxyntomodulin derivative
The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.


07/14/16
20160199429 
 Astragalus membranaceus seed raw oil, refined oil, preparation method therefor and use thereof patent thumbnailAstragalus membranaceus seed raw oil, refined oil, preparation method therefor and use thereof
The invention belongs to the field of traditional chinese medicine (tcm), and in particular relates to an astragalus membranaceus seed raw oil and refined oil extracted from astragalus membranaceus seeds by using a supercritical extraction method, and to a use thereof in the preparation of health-care products. The astragalus membranaceus seed raw oil is obtained by supercritical co2 fluid extraction on the astragalus membranaceus seeds; and the astragalus membranaceus seed refined oil is obtained by physically refining the astragalus membranaceus seed raw oil.
Shanxi Zhendong Pharmaceutical Co. Ltd.


07/14/16
20160199390 
 Animal feed including cationic cholesterol additive and related methods patent thumbnailAnimal feed including cationic cholesterol additive and related methods
Methods and feed compositions for increasing health of agricultural animals incude administering a cationic cholesterol additive through the diet of the animal, such as through solid feed or drinking water of the animals. The method includes feeding an animal a diet comprised of a cationic cholesterol additive, such as a compound with a sterol backbone and a plurality of cationic groups attached thereto.
Brigham Young University


07/14/16
20160199269 
 Method for preparing nanoemulsion patent thumbnailMethod for preparing nanoemulsion
Provided is a method for preparing a nanoemulsion, including mixing an oil phase part (a) containing a ceramide or derivative thereof, cholesterol, non-ionic surfactant, phospholipid and a polyol, a perfume part (b) containing a perfume ingredient, non-ionic surfactant and an alcohol, and an aqueous phase part (c) containing the other water-soluble active ingredients. When a nanoemulsion is obtained by the method, it is possible to reduce processing time and cost since a non-ionic surfactant is used without a high-pressure emulsification process, and the obtained nanoemulsion is more stable against a change in temperature than the other solubilized formulations..
Cosmax, Inc.


07/14/16
20160198752 
 Nutritional and exercise plan based on a person's individual genetic apo e genotype patent thumbnailNutritional and exercise plan based on a person's individual genetic apo e genotype
A nutritional plan based on a person's individual genetic apo e genotype, which has been shown to be the number one gene affecting diet, cholesterol, heart disease, vascular dementia, alzheimer's disease, and chronic illness, possibly autism, parkinson's disease, and other neurological diseases, and that focuses on the right percentages of macronutrients for each individual's genetic type, is disclosed.. .

07/07/16
20160194635 
 Method of enhancing mir-185 expression to reduce low density lipoprotein/cholesterol accumulation in a cell patent thumbnailMethod of enhancing mir-185 expression to reduce low density lipoprotein/cholesterol accumulation in a cell
The present invention provides a method of quantifying mir-185 as a potential biomarker in lipid disorder or cardiovascular diseases in human. The present invention also provides a method of modulating mir-185 in regulating ldl and cholesterol metabolism in cells.
Medical Diagnostic Laboratories, Llc


07/07/16
20160193300 
 Methods of using interleukin-10 for treating diseases and disorders patent thumbnailMethods of using interleukin-10 for treating diseases and disorders
Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to il-10, including methods of administration and dosing regimens associated therewith, are provided, more particularly, the present disclosure relates to optimized dosing parameters to achieve and maintain efficacy in the treatment and/or prevention of metabolic diseases, disorders and conditions in a subject, while minimizing the adverse effects associated therewith. Particular embodiments are directed to the treatment and/or prevention of abnormally high levels of cholesterol and/or manifestation(s) of hypercholesterolemia in as subject..
Armo Biosciences, Inc.


07/07/16
20160193231 
 Rett syndrome and treatments therefore patent thumbnailRett syndrome and treatments therefore
The present invention provides new strategies for the treatment of rett syndrome and other mecp2-associated disorders, including for the identification and/or characterization of useful therapeutic modalities and/or for the stratification of rett syndrome patients to identify those more or less likely to respond to a particular therapy. In some embodiments, the present invention defines certain components of metabolic pathways, and particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways, most particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways in the brain, as targets useful in the identification and/or characterization of potential rett syndrome treatment agents.
Baylor College Of Medicine


07/07/16
20160193173 
 Ketone bodies and ketone body esters as blood lipid lowering agents patent thumbnailKetone bodies and ketone body esters as blood lipid lowering agents
The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or d-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or d-β-hydroxybutyrate, esters of d-β-hydroxybutyrate, oligomers of d-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or r-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services


06/30/16
20160186171 

Agents and methods for inhibiting mir-148a for the modulation of cholesterol levels


Elevated blood levels of low-density lipoprotein-cholesterol (ldl-c, or “bad” cholesterol) are strongly linked to circulatory disorders, e.g. Cardiovascular disease such as atherosclerosis, angina, coronary heart disease, heart attack, stroke, etc.

06/30/16
20160185784 

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as cetp inhibitors


Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, wherein x is —c(═o) or —s(o)2—, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .

06/30/16
20160185720 

Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid


Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and alzheimer's disease.. .

06/23/16
20160177371 

Method of pretreatment of sample for quantitating cholesterol and quantitating cholesterol in specific lipoproteins by using the same


A method of a pretreatment of a sample for quantitating cholesterol characterized by, before measuring cholesterol contained in specific lipoproteins, treating the sample containing lipoproteins with an enzyme, the substrate of which is free cholesterol, optionally together with a reaction accelerator; a method for quantitating cholesterol in specific lipoproteins by using the above method; and a kit for quantitating cholesterol in specific lipoproteins to be used in the above quantification method. By using this quantification method, cholesterol in a specific fraction can be conveniently, accurately and efficiently quantitated fundamentally without resort to polyanion, etc.

06/23/16
20160176913 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

06/23/16
20160175393 

Use of nutritional compositions with phospholipid sphingolipid and cholesterol


A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided.. .

06/23/16
20160174599 

Beverage lowering serum cholesterol


A beverage comprising protein, plant sterol ester and/or plant stanol ester, a fruit and/or vegetable preparation, and a stabiliser.. .

06/09/16
20160161512 

Method and reagent for quantifying cholesterol in high density lipoprotein 3


Disclosed are a method and a reagent for quantifying hdl3 in a test sample without requiring laborious operations. The method for quantifying cholesterol in high-density lipoprotein 3 comprises reacting a test sample with one or more surfactants which react specifically with high-density lipoprotein 3, and quantifying cholesterol.
Denka Seiken Co., Ltd.


06/09/16
20160159883 

Fibronectin based scaffold domain proteins that bind pcsk9


The present invention relates to fibronectin based scaffold domain proteins that bind pcsk9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases.
Bristol-myers Squibb Company


06/09/16
20160158296 

Lactococcus lactis strains for producing bioactive peptides having anti-hypertensive and cholesterol-lowering effects


New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentación Y Desarrollo, A.c. (ciad)


06/02/16
20160151343 

Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College


06/02/16
20160151338 

Nutraceutical composition for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia


A nutraceutical composition is provided for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia, comprising: berberine, monacolin k, 1-deoxynojirimycin (dnj).. .
Akademy Pharma S.r.l.


06/02/16
20160151318 

Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions


The present invention relates to methods of treating lipid disorders, lipid-related disorders or conditions, obesity and obesity-related disorders using nitrated lipids. In particular, the methods comprise administering effective amounts of nitrated fatty acids or esters thereof in order to reduce one or more of triglycerides, free fatty acids, body weight, cholesterol, urine protein excretion and oxidative stress or increase the level of plasma hdl in a subject..
The University Of Utah Research Foundation


05/26/16
20160144037 

Adjuvant compositions and related methods


The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide.
Vaxliant, Llc


05/26/16
20160143963 

Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases


The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species bifidobacterium animalis subsp.
Biopolis, S.l.


05/26/16
20160143942 

Compositions and their use for removing cholesterol


The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide.
Cornell University


05/26/16
20160143837 

Variable color transparent lip balm and preparation method thereof


The present invention provides a variable color transparent lip balm, consisting of following components by weight percent: 4.0 to 5.0% by weight of dibutyl lauroyl glutamide, 2.0 to 3.0% by weight of polyamide-3, 15.0 to 20.0% by weight of bis-stearyl ethylenediamine/neopentyl glycol/stearyl hydrogenated dimer dilinoleate copolymer, 46.65 to 49.60% by weight of c12-15 alkyl benzoate, 1.0 to 3.0% by weight of heptyl undecylenate, 9.0 to 11.0% by weight of c10-30 cholesterol/lanosterol esters, 10.0 to 15.0% by weight of hydrogenated c6-20 polyolefin, 1.5 to 2.5% by weight of dextrin isostearate, 0.05 to 0.1% by weight of eosin yellowish and 0 to 0.8% by weight of excipient. The transparent lip balm of the present invention has good transparency, and excellent variable color effect..
Guangzhou Sheencolor Cosmetics Co., Ltd.


05/26/16
20160143334 

Edible composition suitable for lowering serum cholesterol


The present invention relates to an edible composition comprising plant sterol ester and/or plant stanol ester and triglyceride fat usable for lowering serum ldl cholesterol. The composition further comprises oligosaccharides and sugars.
Raisio Nutrition Ltd


05/19/16
20160139160 

Cardiovascular disease risk assessment


The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers ldl and hdl subfractions, along with lp(a) provides significant improvement in predicting cvd versus standard assays that include standard risk factors.
Boston Heart Diagnostic Corporation


05/19/16
20160138025 

Oligonucleotide conjugates


The present invention relates to oligomeric compounds and conjugates thereof that target proprotein convertase subtilisin/kexin type 9 (pcsk9) pcsk9 mrna in a cell, leading to reduced expression of pcsk9. Reduction of pcsk9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders..
Roche Innovation Center Copenhagen A/s


05/19/16
20160137746 

Methods for treating high cardiovascular risk patients with hypercholesterolemia


The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a pcsk9 inhibitor.
Regeneron Pharmaceuticals, Inc.


05/19/16
20160137745 

Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)


The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a pcsk9 inhibitor.
Regeneron Pharmaceuticals, Inc.


05/19/16
20160136236 

Compositions and methods of altering cholesterol levels


The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmrna molecules. The present invention also relates to compositions and methods for altering cholesterol levels using polynucleotides, primary transcripts and mmrna molecules..
Moderna Therapeutics, Inc.


05/19/16
20160136217 

Composition containing composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms


The present invention relates to a composition and functional health food containing a composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms; and a method for preventing or treating menopausal symptoms by administering the composite extract. The composite extract of rehmannia glutinosa and pueraria lobata of the present invention can ameliorate weight increase, which is the representative symptom of menopausal women, and can effectively improve osteoporosis and blood cholesterol.
University-industry Cooperation Group Of Kyung Hee University


05/19/16
20160136121 

Use of cilastatin to reduce the nephrotoxicity of different compounds


Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts.
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon


05/12/16
20160129017 

Ship inhibition to combat obesity


The present invention relates to the use of ship1 inhibitors and pan-ship1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.. .
The Research Foundation For The State University New York


05/12/16
20160128967 

Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids


A composition and a method of treatment utilizing a combination of statins (or hmg-coa reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme hmg-coa reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition, the compositions and method designed to stabilize vulnerable plaque while mediating omega-3 deficiencies in individuals in need thereof.. .
Pivotal Therapeutics Inc.


05/05/16
20160122387 

Angiotensin peptide and pharmaceutical compositions for disease treatment


The present invention relates to the peptide (arg0) n-angiotensin-(1-7) [(arg0) n-ang-(1-7)], where n is 1 to 10 (xaa-asp-arg-val-tyr-ile-his-pro; seq id no:1 where xaa represents 1 to 10 l-arg residues), which is produced by inserting at least one arginine amino acid at the amino terminal position of ang-(1-7), as well as pharmaceutical compositions containing this peptide and the use thereof for the treatment or prevention of diseases or disorders that are due or associated with reduced nitric oxide production. Non-limiting examples of these diseases or disorders are cardiopulmonary and liver diseases, vascular disorders, metabolic disorders, neural disorders, genito-urinary tract disorders, skeletal muscle disorders, kidney disorders, skin disorders, alopecia or tumors.
Universidade Federal De Minas Gerais - Ufmg


05/05/16
20160120963 

Bile salt hydrolase bsh1 for regulating weight gain, serum cholesterol levels, and liver triglycerides in a mammal; bacteria strains expressing bsh1 variants


A non-therapeutic method of reducing weight gain, serum cholesterol levels, or liver triglyceride levels, in a non-obese mammal, comprises the step of administering to the gut of a mammal an effective amount of a bacteria expressing a bsh1 enzyme of sequence id no: 1, or a functional variant thereof; a bsh1 enzyme of sequence id no: 1, or a functional variant thereof for use as a medicament; isolated bacterial strains expressing functional variants of bsh1.. .
University College Cork, National University Of Ireland


04/28/16
20160115211 

Compositions and methods for regulating angiogenesis and cholesterol and treating dyslipidemia, atherosclerosis, cancer and inflammatory conditions


The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of apoa-1 binding protein (apoaibp, aibp, or ai-bp), and methods for making and using them. In alternative embodiments, apoaibp-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularization, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia.
The Regents Of The University Of California


04/28/16
20160115167 

Bmp inhibitors and methods of use thereof


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
The General Hospital Corporation


04/28/16
20160115138 

Inhibitors of cholesterol ester transfer protein


The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors..
Concert Pharmaceuticals, Inc.


04/28/16
20160113874 

Novel catatonic lipids with various head groups for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with sirna, to facilitate the cellular uptake and endosomal escape, and to knockdown target mrna both in vitro and in vivo.. .
Sirna Therapeutics. Inc.


04/28/16
20160113873 

Nanocarrier therapy for treating invasive tumors


Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis.
Children's Healthcare Of Atlanta, Inc.


04/21/16
20160109469 

Method of measuring lipoprotein's capacity to accept cholesterol


Measuring the label incorporated into the complex.. .

04/21/16
20160108082 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

04/21/16
20160106750 

Compounds for the prevention and treatment of cardiovascular diseases


The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein a-i (apoa-i), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.. .

04/21/16
20160106077 

Transgenic animal expressing alzheimer's tau protein


The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harbouring a human dna sequence encoding alzheimer's disease (ad) derived tau protein, capable of inducing ad pathology in transgenic animals. Alzheimer's tau protein is expressed on specific genetic backgrounds allowing also simulation of different human diseases including hypertension, diabetes, hyper-cholesterolemia, which are associated with neurodegeneration and are considerable risk factors for ad development.

04/14/16
20160102126 

Novel peptides involved in energy homeostasis


The expression of a mrna encoding a putative 76 amino acid, secreted protein (“enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of enho1 mrna in two mouse models of obesity, kk-ay and lepob/lepob mice.

04/14/16
20160102074 

Substituted amide compounds


The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .

04/14/16
20160101124 

Nano-liposomal aminoglycoside-thymoquinone formulations


The nano-liposomal aminoglycoside-thymoquinone formulations are suitable for administration to a mammal and include an aminoglycoside antibiotic (amikacin, gentamicin, or tobramycin) and thymoquinone (tq) encapsulated within a liposome. The liposome-encapsulated aminoglycoside-thymoquinone (tq) formulations can be administered to a subject in need thereof.

04/07/16
20160096898 

Pc33718e


The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (pcsk9). Also provided are antibodies directed to peptides, in which the antibodies bind to pcsk9.
Rinat Neuroscience Corp.


04/07/16
20160095889 

Composition and use of lactobacillus reuteri gmnl-263 in decreasing blood lipid levels


A use of a lactobacillus reuteri gmnl-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri gmnl-263 (accession no.: cctcc m 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism.
Genmont Biotech Inc.


04/07/16
20160095888 

Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders


This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain.
Aker Biomarine Antarctic As


04/07/16
20160095835 

Compositions containing omega-3 oil and uses thereof


The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.


03/31/16
20160089355 

Composition for preventing the occurrence of cardiovascular event in multiple risk patient


Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with hmg-coa ri or a cardiovascular event occurring in a multiple risk patient.. .
Mochida Pharmaceutical Co., Ltd.


03/24/16
20160084858 

Systems and methods for non-fasting ldl cholesterol assays


In one embodiment, a test strip for testing for cholesterol-related blood analytes in whole blood includes a red blood cell separation layer, the red blood cell separation layer separating red blood cells from a blood sample applied to the test strip as the blood sample flows downward through the red blood cell separation layer. The test strip further includes a reaction layer receiving the blood sample from the red blood cell separation layer, the reaction layer including poe-pop-poe block copolymer, a surfactant, and a reflectivity changing reactant, the poe-pop-poe block copolymers solubilizing essentially only non-ldl cholesterol analytes, the non-ldl cholesterol analytes reacting with the reflectivity changing reactant in order to change a reflectivity of the blood sample..
Polymer Technology Systems, Inc.


03/24/16
20160083425 

Proprotein convertase subtilisin kexin type 9 (pcsk9) allosteric binding ligands to modulate serum low density lipoprotein (ldl) levels


This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein pcsk9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 da.
Srx Cardio, Llc


03/24/16
20160082061 

Nutritional composition and manufacture


A nutritional composition, and method of making it, that includes a carbohydrate, an insulin potentiator, an amino acid, a muscle growth stimulator, an energy increaser, at least one natural supplement for weight loss, reduction of cholesterol levels, and/or increased resistance to stress, and at least one flavoring ingredient. The composition may be provided in dry form for addition to a fluid or in liquid forms.

03/24/16
20160081994 

Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects


The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the mtp inhibitor to the subject.
The Trustees Of The University Of Pennsylvania


03/24/16
20160081385 

Process


A method for reducing the amount of cholesterol and/or improving the texture and/or reducing weight loss and/or increasing the fat stability of a meat based food product comprising: a) contacting meat with a lipid acyltransferase; b) incubating the meat contacted with the lipid acyltransferase at a temperature between about 1° c. To about 70° c.; c) producing a food product from the meat; wherein step b) is conducted before, during or after step c).
Dupont Nutrition Biosciences Aps


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074419 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

03/17/16
20160074417 

Sr-bi as a predictor of human female infertility and responsiveness to treatment


Methods of diagnosis and treatment of diseases and disorders related to de novo synthesis of cholesterol, based on allelic variants of the scavenger receptor class b type i receptor, and kits for use therein.. .
The Johns Hopkins University


03/17/16
20160074384 

Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery


Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by mns reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window.
University Of Kentucky Research Foundation


03/17/16
20160074363 

Methods for improving lipid profiles using atrasentan


The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum ldl cholesterol, relative to the subject's baseline serum ldl cholesterol.. .
Abbvie Inc.


03/10/16
20160068812 

Method for culturing skeletal muscle for tissue engineering


The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (deta); verifying deta monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the deta monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating.
University Of Central Florida Research Foundation, Inc.


03/10/16
20160067243 

Ketoconazole enantiomer in humans


Treatment of patients with the 2s,4r ketoconazole enantiomer or its pharmaceutically acceptable salts, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.. .
Cortendo Ab (publ)


03/03/16
20160058768 

Substituted amide compounds


The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .
Pfizer Inc.


02/25/16
20160054305 

Method for measuring bile salt export transport and/or formation activity


A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, dna, rna. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ.
Biotranex, Llc


02/18/16
20160046633 

Bmp inhibitors and methods of use thereof


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
The U.s.a., As Represented By The Secretary, Department Of Health & Human Services


02/18/16
20160046575 

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)


Novel forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, form xxv, form xxvi, form xxvii, form xxviii, form xxix, and form xxx, characterized by their x-ray powder diffraction, solid-state nmr, and/or raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer's disease.. .
Warner-lambert Company Llc


02/18/16
20160045595 

Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds


A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from quillaja saponaria molina (quilq) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a quil a micelle and by an hydrophilic ester bond between a sterol oh− and cooh− or aldehyde groups in the quila micelle.
Moreinx Ab


02/11/16
20160039945 

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9


The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr. In embodiments, the antigen binding proteins specifically bind pcsk9.
Amgen Inc.


02/11/16
20160039804 

Novel oxazolidinone derivative as cetp inhibitor, its preparation method, and pharmaceutical composition comprising the same


Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against cetp, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against cetp, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various cetp enzyme activity- or hdl cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease..
Dong-a St Co., Ltd.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7968

5109

3 - 0 - 102